Evidence map›Paper›PMID 36434633›Full record

ArticleCardiovascular diabetology2022

The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus.

Carlos Puig-Jové, Josep Julve, Esmeralda Castelblanco, M Teresa Julián, Núria Amigó, Henrik U Andersen, Tarunveer S Ahluwalia, Peter Rossing, Dídac Mauricio, Magnus T Jensen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Carlos Puig-Jové *Department of Endocrinology & Nutrition, University Hospital Mútua de Terrassa, Terrassa, Spain.
Josep Julve *Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Esmeralda CastelblancoDivision of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine in St. Louis, St Louis, MO, USA.
M Teresa JuliánCenter for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Núria AmigóCenter for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Henrik U AndersenSteno Diabetes Center Copenhagen, Herlev, Denmark.
Tarunveer S AhluwaliaSteno Diabetes Center Copenhagen, Herlev, Denmark.
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.
Dídac MauricioCenter for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Magnus T JensenDepartment of Cardiology, Copenhagen University Hospital Amager Hvidovre, Copenhagen, Denmark.
Núria AlonsoDepartment of Medicine, Autonomous University of Barcelona (UAB), Barcelona, Spain. nalonso32416@yahoo.es.
Instituto de Salud Carlos III · ESSteno Diabetes Center · DKCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESCopenhagen University Hospital · DKUniversitat de Vic - Universitat Central de Catalunya · ESUniversity Hospital Mútua de Terrassa · ESUniversity of Copenhagen · DKWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM.

methodsWe included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e'≥12 or E/e' 8-12 + volume of the left atrium > 34 ml/m2. To identify a metabolic profile associated with the presence of subclinical myocardial dysfunction, a multivariate supervised model of classification based on least squares regression (PLS-DA regression) was performed.

resultsOne-hundred forty-six subjects had diastolic dysfunction and 18 systolic dysfunction. Compared to the control group, patients with myocardial dysfunction had longer duration of diabetes (p = 0.005), and higher BMI (p = 0.013), serum NTproBNP concentration (p = 0.001), systolic blood pressure (p < 0.001), albuminuria (p < 0.001), and incidence of advanced retinopathy (p < 0.001). The supervised classification model identified a specific pattern associated with myocardial dysfunction, with a capacity to discriminate patients with myocardial dysfunction from controls. PLS-DA showed that triglyceride-rich lipoproteins (TGRLs), such as VLDL (total VLDL particles, large VLDL subclass and VLDL-TG content) and IDL (IDL cholesterol content), as well as the plasma concentration of GlycA, were associated with the presence of subclinical myocardial dysfunction.

conclusionProatherogenic TGRLs and the proinflammatory biomarker Glyc A are strongly associated to myocardial dysfunction in T1DM. These findings suggest a pivotal role of TGRLs and systemic inflammation in the development of subclinical myocardial dysfunction in T1DM.

Indexed as

CardiomyopathiesDiabetes Mellitus, Type 1Ventricular Dysfunction, LeftBiomarkersGlycosylationHumansLipoproteinsStroke VolumeTriglyceridesVentricular Function, LeftBiomarkersLipoproteinsTriglyceridesGlycAHeart failureLipoproteinsMyocardial dysfunctionType 1 diabetes

Identifiers

PMID36434633
PMCPMC9700974
OpenAlexW4310046102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.